Skip to main content
    F

    Fractyl Health, Inc. Common Stock (GUTS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.16
    +0.08 (+1.96%)

    Market Cap: $54.12M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    70%(7/10)
    Avg Surprise
    +7.24%
    Streak
    3 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.50
    Range$-1.62 - $-1.32
    4 analysts
    EPS Revisions
    3
    0
    7d
    3
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.66+9.9%
    60d ago$-1.66+9.9%
    30d ago$-1.47-1.7%
    7d ago$-1.47-1.7%
    Current$-1.50
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-2.18
    Range$-2.33 - $-1.93
    4 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-2.18---
    Sep 26EST
    		-$-1.50---
    Jun 26
    Reported Aug 10
    		$-0.12$-0.15+20.00%Beat+78.9%
    Mar 26
    Reported May 12
    		$0.06N/A+114.20%Beat+111.9%
    Dec 25
    Reported Mar 24
    		$-0.07N/A+61.11%Beat+86.5%
    Sep 25
    Reported Nov 12
    		$-0.71$-0.32-121.88%Miss-65.1%
    Jun 25
    Reported Aug 12
    		$-0.57$-0.36-58.33%Miss-58.3%
    Mar 25
    Reported May 13
    		$-0.49$-0.50+2.00%Beat-188.2%
    Dec 24
    Reported Mar 3
    		$-0.52$-0.42-23.81%Miss-
    Sep 24
    Reported Nov 12
    		$-0.43$-0.50+14.00%Beat-
    Jun 24
    Reported Aug 14
    		$-0.36$-0.46+21.74%Beat-
    Mar 24
    Reported Apr 1
    		$-0.17$-0.30+43.33%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.41EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-778.00%ROIC-245.76%
    Financial Health
    Debt/Equity-21.40xInterest CoverageN/A
    Current Ratio3.15xQuick Ratio3.15x
    Trading Statistics
    Beta2.42Avg Volume1.38M
    52-Week High$29.3452-Week Low$3.78

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.39
    SMA 20$5.28
    SMA 50$7.02
    SMA 200$9.19
    EMA 10$4.53
    EMA 20$5.21
    EMA 50$6.55
    EMA 200$9.40

    MACD

    Line: -0.89Signal: -0.86Hist: -0.03

    ADX

    ADX: 45.5+DI: 5.2-DI: 1.7

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down64.0
    PSAR$1.06

    Bollinger Bands

    Upper Band$7.34
    Lower Band$3.23
    %B Position7772%(Upper)
    Band Width0.23

    RSI (14-Day)

    Oversold
    29.1

    Momentum Oscillators

    Stoch %K83.6
    Stoch %D85.7
    Williams %R-14.8
    ROC (10d)-23.0%
    Momentum-1.24
    CCI (20d)57.0
    MFI (14d)35.7

    Volatility Measures

    ATR (14d)$3.50(84.2%)
    StdDev (20d)1.03
    Hist Vol103.6%(High)

    Volume Flow

    VWAP$4.10
    OBV-36.0M
    AD Line210.4B
    CMF (20d)210.580

    Volume Metrics

    Avg Vol (20d)1.4M
    Vol Ratio0.1x(Low)
    VWMA (20d)$5.76

    Pivot Points

    R3$4.70
    R2$4.45
    R1$4.27
    Pivot Point$4.02
    S1$3.84
    S2$3.59
    S3$3.41

    Advanced Oscillators

    TSI-41.49
    Ultimate Osc63.1
    KST-393.67

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$3,000$14,000$43,000$33,000$7,000$36,000
    Cost of RevenueN/AN/A$279,000$290,000$270,000$290,000$-53,000$7,000$24,000$19,000$40,000$109,000
    Gross Profit$0N/A$-279,000$-290,000$-270,000$-290,000$3,000$7,000$19,000$14,000$-33,000$-73,000
    Operating Expenses$19.10M$20.82M$23.28M$22.69M$26.08M$24.76M$25.21M$23.80M$23.00M$21.56M$12.95M$13.80M
    R&D$13.81M$15.60M$16.49M$17.46M$21.15M$19.43M$20.28M$19.00M$16.76M$14.42M$10.17M$9.38M
    SG&A$5.28M$5.22M$6.79M$5.24M$4.93M$5.32M$4.93M$4.80M$6.24M$7.13M$2.82M$5.52M
    Operating Income$-19,096,000$-20,820,000$-23,284,000$-22,694,000$-26,079,000$-24,759,000$-25,210,000$-23,794,000$-22,985,000$-21,542,000$-12,981,000$-13,873,000
    Interest Income$431,000$593,000$645,000$166,000$226,000$503,000$726,000$947,000$1.38M$1.10M$463,000$226,000
    Interest Expense$6.44M$0$20.44M$22.91M$1.81M$0$0$0$0$0$6.20M$1.87M
    Income Before Tax$-25,538,000$9.22M$-43,727,000$-45,603,000$-27,889,000$-23,735,000$-24,970,000$-23,173,000$-17,229,000$-3,322,000$-19,180,000$-15,747,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-25,538,000$9.22M$-43,727,000$-45,603,000$-27,889,000$-23,735,000$-24,970,000$-23,173,000$-17,229,000$-3,322,000$-19,180,000$-15,747,000
    EBITDA$-25,260,000$9.50M$-43,448,000$-45,313,000$-27,619,000$-23,445,000$-24,747,000$-22,964,000$-17,037,000$-3,269,000$-12,943,000$-15,663,000
    EBIT$-25,538,000$9.22M$-43,727,000$-45,603,000$-27,889,000$-23,735,000$-24,970,000$-23,173,000$-17,229,000$-3,322,000$-12,981,000$-15,747,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about GUTS

    News

    GUTS Stock Slumps As Revita Trial Fallout Fuels Lawsuits

    Fractyl Health, Inc. (GUTS) stock has plummeted over 52% due to concerns regarding its Revita clinical trial. Multiple securities class actions have been filed...

    www.timothysykes.com•10/16/26•Neutral

    GUTS Stock Reels As Revita Trial Fallout Fuels Class Actions

    Shares of Fractyl Health (NASDAQ:GUTS) experienced a significant collapse after weak six-month REMAIN-1 Midpoint Cohort data and the disclosure of an outlier trial site. This led to a sweeping securities class action...

    StocksToTrade•10/16/26•Bearish

    Fractyl Health reports positive results from weight maintenance trial By Investing.com

    Fractyl Health announced positive six-month results from its REMAIN-1 study for its Revita DMR System, showing participants maintained approximately 80% of GLP-1-induced weight loss compared to 67% for a sham procedure...

    Investing.com Canada•10/16/26•Bullish

    About 80% of GLP-1 weight loss stayed off at six months in Fractyl Health (GUTS) Revita trial

    Fractyl Health (GUTS) announced positive six-month results from its REMAIN-1 Pivotal Cohort study for the Revita DMR System...

    Stock Titan•10/16/26•Bullish

    Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation

    Fractyl Health announced positive six-month results from its REMAIN-1 pivotal study for Revita, a procedure aimed at weight maintenance after discontinuing GLP-1 therapy. The study showed that Revita participants...

    Stock Titan•10/16/26•Bullish

    GUTS Valuation and Fair Value

    P/E
    -0.4x
    P/B
    -33.0x
    See GNG's fair value

    GUTS Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROIC
    -245.8%
    ROE
    -778.0%
    FCF margin
    -2747966.7%

    GUTS Competitors

    CompanyTicker
    Gossamer Bio IncGOSS
    Kezar Life Sciences IncKZR
    Pliant Therapeutics IncPLRX
    DarioHealth CorpDRIO
    Talphera Inc.TLPH
    Kalaris Therapeutics, Inc.KLRS
    RenovoRx IncRNXT
    Inspira Technologies Oxy BHN LtdIINN

    Sector: Healthcare

    GUTS Analyst Ratings

    Consensus
    Buy
    Analysts
    7
    Strong Buy
    0
    Buy
    6
    Hold
    1
    Sell
    0
    Strong Sell
    0

    GUTS Bull Case vs Bear Case

    Bull case

    • 85.7% of GUTS's analyst ratings are Buy or Strong Buy.

    Bear case

    • GUTS's quarterly revenue changed -57.1% year over year.

    GUTS Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    0.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.50
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    3 up, 0 down

    Frequently Asked Questions About GUTS

    Does GUTS pay dividends?

    Fractyl Health, Inc. Common Stock (GUTS) does not currently pay a regular dividend.

    What is GUTS's market cap?

    Fractyl Health, Inc. Common Stock (GUTS) has a market capitalization of $54.12M with a current stock price of $4.16.

    Related stocks

    Sector: Healthcare

    All stocks starting with G

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In